Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Experimental hematology & oncology - 10(2021), 1 vom: 04. Jan., Seite 1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jasra, Sakshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.01.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s40164-020-00186-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319613909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319613909 | ||
| 003 | DE-627 | ||
| 005 | 20231225171826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40164-020-00186-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319613909 | ||
| 035 | |a (NLM)33397455 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jasra, Sakshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.01.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax | ||
| 650 | 4 | |a Letter | |
| 700 | 1 | |a Kazemi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nishi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiahao |e verfasserin |4 aut | |
| 700 | 1 | |a Fehn, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanhua |e verfasserin |4 aut | |
| 700 | 1 | |a Mantzaris, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Kornblum, Noah |e verfasserin |4 aut | |
| 700 | 1 | |a Sica, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bachier, LizaMarie |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfinger, Mendel |e verfasserin |4 aut | |
| 700 | 1 | |a Gritsman, Kira |e verfasserin |4 aut | |
| 700 | 1 | |a Braunschweig, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Steidl, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Shastri, Aditi |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental hematology & oncology |d 2012 |g 10(2021), 1 vom: 04. Jan., Seite 1 |w (DE-627)NLM223165115 |x 2162-3619 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:04 |g month:01 |g pages:1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40164-020-00186-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 1 |b 04 |c 01 |h 1 | ||